聯化科技(002250.SZ):實控人牟金香擬減持不超2000萬股
格隆匯5月12日丨聯化科技(002250.SZ)公佈,公司控股股東、實際控制人牟金香持有公司股份254,535,853股,佔公司總股本的27.57%。現因個人資金需求,牟金香擬通過大宗交易或集中競價交易的方式減持其持有的部分公司股份。
此次擬減持股份將不超過2000萬股,佔公司總股本的2.17%;其中,通過集中競價交易方式減持不超過1846萬股,佔公司總股本的2%。大宗交易方式減持的期間為自公吿之日起三個交易日後的六個月內,集中競價交易方式減持的期間為自公吿之日起十五個交易日後的六個月內(窗口期不得減持)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.